Phase 3 N=4 Treating Bacterial Overgrowth in Parkinson's Disease
Parkinson's Disease · Small Intestinal Bacterial Overgrowth
Primary: Change in "Off" Time as Measured by Patient Diary — -1.4; -2.8; -0.9; -2.0 hours
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=615 A Study of MD-120 in Patients With Depression
Major Depressive Disorder
Primary: Changes in Total MADRS Score From the Baseline to Week 8 Visit During the Treatment Period — -10.4; -11.1; -11.9 Score on a scale — p=0.509
Phase 3 N=189 Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients
Amyotrophic Lateral Sclerosis (ALS)
Primary: The Proportion of NurOwn® Treated Participants With a ≥1.25 Points/Month Improvement in Post-treatment Slope vs. Pre-treatment Slope in ALSFRS-R Score at 28 Weeks…
Phase 3 N=939 Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation
Chronic Obstructive Pulmonary Disease
Primary: Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-Week Treatment Period — 1.01; 0.776 exacerbation per…
Phase 3 N=1,490 A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)
Respiratory Syncytial Virus Infections
Primary: Number of Participants With MA RSV LRTI Through 150 Days Post Dose (Primary Cohort) — 25; 12; 6; 15 Participants — p=<0.0001
Phase 3 N=14 Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis
Dermatomyositis · Idiopathic Inflammatory Myopathies
Primary: Change in Calcinosis Activity Visual Analogue Scale Score — -3.45 Units on a scale
Phase 3 N=175 Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
Diabetes Mellitus, Type 2
Primary: Change in Glycated Haemoglobin (HbA1c) (%) From Baseline to the End of 26 Weeks - DINAMOᵀᴹ — NA; 0.33; -0.17; -0.49 Percent change — p=0.2935
Phase 3 N=60 A Study to Compare the Effectiveness of Adductor Canal Pain Catheters Following Total Knee Arthroplasty
Osteoarthritis, Knee
Primary: Post-operative Pain Levels — 5.1; 5.1; 6.1 score on a scale
Phase 3 N=82 Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)
Cold Urticaria
Primary: Percentage of Participants With Negative Ice Cube Provocation Test at Week 24 — 37.5; 40.5 percentage of participants — p=0.9492
Phase 3 N=71 Phase 3 Study of SNF472 for Calciphylaxis
Calciphylaxis · Calcific Uremic Arteriolopathy
Primary: Absolute Change in the BWAT - CUA Score for the Primary Lesion — -5.3; -6.0 score on a scale — p=0.877
Phase 3 N=1,208 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)
Covid19
Primary: Time to Sustained Recovery in Days — 10; 10 days
Phase 3 N=444 A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis
Lung Diseases, Interstitial
Primary: Number of Patients With Any Adverse Event (AE) Over the Course of the Trial — 441 Participants
Phase 3 N=1,148 A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
Depressive Disorder, Treatment-Resistant
Primary: Change From Study Baseline in Computerized Cognitive Battery Domain Score: Detection Test (DET) Score — 0.0218; -0.0065 log10 msec
Phase 3 N=331 Placebo Controlled Clinical Trial of the Postoperative Opioid Sparing Effects of Intraoperative Dexmedetomidine Infusion for Thoracic Surgery
Pain
Primary: Total Opioid Administered — 4.0; 6.0 Morphine Milligram Equivalents
Phase 3 N=43 A Clinical Study to Evaluate the Maximum Maxillary Bite Force (BF) When Using Two Novel Denture Adhesives Compared to Using No-Adhesive
Denture Retention
Primary: Area Over Baseline Over 12 Hours (AOB 0-12) to Compare Maximum Incisal Bite Force — 0.87; 0.69; 0.89; 0.59 lbs — p=0.037